文献速递脊柱关节炎

脊柱关节炎患者葡萄膜炎的患病率与发病率:生物制剂时代的影响——来自国际ASAS-COMOSPA研究的数据

Prevalence and incidence of uveitis in patients with spondyloarthritis: the impact of the biologics era. Data from the international ASAS-COMOSPA study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

ASAS-COMOSPA回顾性研究纳入22个国家3984例符合ASAS脊柱关节炎分类标准的患者,评估葡萄膜炎患病率及其与地理区域和生物制剂时代的关系。葡萄膜炎患病率从诊断时10.5%升至诊断后30年46.6%;2000年后发病者患病率8.2%低于2000年前25.5%,发病率2.8/100人年也低于6.1/100人年。

要点

  • 葡萄膜炎患病率从脊柱关节炎诊断时10.5%(95%CI 9.5-11.4%)升至诊断后30年46.6%(95%CI 41.6-51.5%)。
  • HLA-B27阳性、葡萄膜炎家族史、外周起止点炎和炎症性肠病与葡萄膜炎风险升高相关。
  • 2000年后发病者葡萄膜炎患病率8.2% vs 2000年前25.5%(P<0.01),发病率2.8/100人年 vs 6.1/100人年。

核心结论

  • 本研究中至少发生过一次葡萄膜炎的风险从轴性脊柱关节炎诊断时约10%升至病程30年时约47%。
  • 2000年生物制剂时代开始后发病的患者,首次葡萄膜炎发作的患病率和发病率均显著低于2000年前发病者。

研究设计与样本

  • ASAS-COMOSPA为回顾性研究,纳入22个国家符合ASAS脊柱关节炎分类标准的患者。
  • 共纳入3984例患者,计算总体葡萄膜炎患病率,采用Cox回归评估首次葡萄膜炎发作相关因素,并用Log-Rank检验比较非生物制剂时代(2000年前脊柱关节炎发病)与生物制剂时代(2000年后发病)的葡萄膜炎新发情况。

主要发现

  • 首次葡萄膜炎发作的可能性随时间增加,患病率从脊柱关节炎诊断时10.5%(95%CI 9.5-11.4%)升至诊断后30年46.6%(95%CI 41.6-51.5%)。
  • HLA-B27阳性、葡萄膜炎家族史、外周起止点炎和炎症性肠病与葡萄膜炎风险升高相关。
  • 2000年后发病者葡萄膜炎患病率8.2% vs 2000年前发病者25.5%(P<0.01)。
  • 2000年后发病者葡萄膜炎发病率2.8/100人年 vs 2000年前发病者6.1/100人年。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Uveitis is a common extra-musculoskeletal manifestation in SpA. The aim of this study was to analyze the prevalence of uveitis in SpA patients, and its association with geographical areas, and to determine whether its incidence differed between before and after the biologics era. METHODS: ASAS-COMOSPA is a retrospective study that includes patients fulfilling Assessment in SpondyloArthritis International Society (ASAS) SpA classification criteria from 22 countries. The overall prevalence of uveitis was calculated, and factors associated with the onset of a first episode of uveitis were evaluated using a Cox regression. A Log-Rank test was performed to compare the new onset of uveitis in the non-biologics era (SpA onset before 2000) vs biologics era (SpA onset after 2000). RESULTS: A total of 3984 patients were included. The likelihood of presenting a first uveitis episode increased over time, from a prevalence of 10.5% (95% CI 9.5-11.4%) at the time of the SpA diagnosis to 46.6% (41.6-51.5%) after 30 years since the SpA diagnosis. HLA-B27 positivity, family history of uveitis, peripheral enthesitis, and IBD were associated with higher risk of uveitis. Patients with SpA disease onset after the year 2000 showed a lower prevalence of uveitis compared with those with disease onset before the year 2000 (8.2% vs 25.5%, P <0.01), as well as a lower incidence (2.8 per 100 person-years vs 6.1 per 100 person-years, respectively). CONCLUSION: In our study, the risk of having suffered from at least one episode of uveitis ranged from 10% at the time of the diagnosis of axial SpA to 47% after 30 years of disease duration. Patients with disease onset after biologic therapy introduction showed a significantly lower prevalence and incidence of first episodes of uveitis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Maldonado-Ficco H, López-Medina C, Perez-Alamino R, et al. Prevalence and incidence of uveitis in patients with spondyloarthritis: the impact of the biologics era. Data from the international ASAS-COMOSPA study. Rheumatology (Oxford). 2025. PMID: 39361425. doi:10.1093/rheumatology/keae536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。